Outcome in children with Down's syndrome and acute lymphoblastic leukemia: Role of IKZF1 deletions and CRLF2 aberrations

Leukemia

Volumn 26, Issue 10, 2012, Pages 2204-2211

  Buitenkamp, T D ^a   Pieters, R ^a   Gallimore, N E ^a   Van Der Veer, A ^a   Meijerink, J P P ^a   Beverloo, H B ^b,c   Zimmermann, M ^d   De Haas, V ^e   Richards, S M ^f   Vora, A J ^g   Mitchell, C D ^h   Russell, L J ⁱ   Schwab, C ⁱ   Harrison, C J ⁱ   Moorman, A V ⁱ   Van Den Heuvel Eibrink, M M ^a   Den Boer, M L ^a   Zwaan, C M ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Working Group Hematologic Genome Diagnostics   (Netherlands)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^h JOHN RADCLIFFE HOSPITAL   (United Kingdom)

ⁱ NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

ALL; CRLF2; Down's syndrome; IKZF1; Prognosis

Indexed keywords

CYTOKINE RECEPTOR LIKE FACTOR 2; IKAROS FAMILY ZINC FINGER 1; IKAROS TRANSCRIPTION FACTOR; JANUS KINASE 2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B LYMPHOCYTE; CELL MATURATION; CHILD; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DOWN SYNDROME; EVENT FREE SURVIVAL; FEMALE; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENE REARRANGEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

CHILD, PRESCHOOL; COMPARATIVE GENOMIC HYBRIDIZATION; DOWN SYNDROME; FEMALE; GENE DELETION; GENE EXPRESSION PROFILING; HUMANS; IKAROS TRANSCRIPTION FACTOR; IN SITU HYBRIDIZATION, FLUORESCENCE; JANUS KINASE 2; MALE; MULTIVARIATE ANALYSIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, CYTOKINE;

EID: 84867403265     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.84     Document Type: Article

References (44)

1. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000; 355: 165-169. (Pubitemid 30068214)
2. Rainis L, Bercovich D, Strehl S, Teigler-Schlegel A, Stark B, Trka J et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood 2003; 102: 981-986. (Pubitemid 36917793)
3. Vyas P, Crispino JD. Molecular insights into Down syndrome-associated leukemia. Curr Opin Pediatr 2007; 19: 9-14. (Pubitemid 46114752)
4. Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002; 32: 148-152. (Pubitemid 34977210)
5. Forestier E, Izraeli S, Beverloo B, Haas O, Pession A, Michalova K et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood 2008; 111: 1575-1583. (Pubitemid 351213448)
6. Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008; 372: 1484-1492.
7. Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin MG, Liu W, Zhang J et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 2009; 41: 1243-1246.
8. Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009; 114: 2688-2698.
9. Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 2010; 115: 1006-1017.
10. Gaikwad A, Rye CL, Devidas M, Heerema NA, Carroll AJ, Izraeli S et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol 2009; 144: 930-932.
11. Kearney L, Gonzalez De Castro D, Yeung J, Procter J, Horsley SW, Eguchi-Ishimae M et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 2009; 113: 646-648.
12. Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia Proc Natl Acad Sci USA 2009; 106: 9414-9418.
13. Cario G, Zimmermann M, Romey R, Gesk S, Vater I, Harbott J et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 2010; 115: 5393-5397.
14. Harvey RC, Mullighan CG, Chen IM, Wharton W, Mikhail FM, Carroll AJ et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010; 115: 5312-5321.
15. Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2010; 107: 252-257.
16. Ensor HM, Schwab C, Russell LJ, Richards SM, Morrison H, Masic D et al. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial Blood 2011; 117: 2129-2136.
17. Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009; 10: 125-134.
18. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360: 470-480.
19. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758-764. (Pubitemid 46582031)
20. Loudin MG, Wang J, Eastwood Leung HC, Gurusiddappa S, Meyer J Condos G et al. Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. Leukemia 2011; 25: 1555-1563.
21. Kamps WA, Bokkerink JP, Hakvoort-Cammel FG, Veerman AJ, Weening RS, van Wering ER et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia 2002; 16: 1099-1111. (Pubitemid 34624558)
22. Veerman AJ, Kamps WA, van den Berg H, van den Berg E, Bokkerink JP, Bruin MC et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol 2009; 10: 957-966.
23. Qureshi A, Mitchell C, Richards S, Vora A, Goulden N. Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe Br J Haematol 2010; 149: 410-413.
24. Hann I, Vora A, Richards S, Hill F, Gibson B, Lilleyman J et al. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia. Leukemia 2000; 14: 356-363. (Pubitemid 30142855)
25. Kaspers GJ, Veerman AJ, Pieters R, Broekema GJ, Huismans DR, Kazemier KM et al. Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. Br J Cancer 1994; 70: 1047-1052. (Pubitemid 24358937)
26. Harrison CJ, Martineau M, Secker-Walker LM. The Leukaemia Research Fund/United Kingdom Cancer Cytogenetics Group Karyotype Database in acute lymphoblastic leukaemia: a valuable resource for patient management. Br J Haematol 2001; 113: 3-10. (Pubitemid 32423294)
27. Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 2010; 11: 429-438.
28. Van Vlierberghe P, van Grotel M, Beverloo HB, Lee C, Helgason T, Buijs-Gladdines J et al. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood 2006; 108: 3520-3529.
29. Kuiper RP, Waanders E, van der Velden VH, van Reijmersdal SV, Venkatachalam R, Scheijen B et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia 2010; 24: 1258-1264.
30. Blink M, Buitenkamp TD, van den Heuvel-Eibrink MM, Danen-van Oorschot AA, de Haas V, Reinhardt D et al. Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia Leukemia 2011; 25: 1365-1368.
31. Balgobind BV, Van den Heuvel-Eibrink MM, De Menezes RX, Reinhardt D Hollink IH, Arentsen-Peters ST et al. Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Haematologica 2011; 96: 221-230.
32. Schwab CJ, Jones LR, Morrison H, Ryan SL, Yigittop H, Schouten JP et al. Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer 2010; 49: 1104-1113.
33. Tissing WJ, Meijerink JP, Brinkhof B, Broekhuis MJ, Menezes RX, den Boer ML et al. Glucocorticoid-induced glucocorticoid-receptor expression and promoter usage is not linked to glucocorticoid resistance in childhood ALL. Blood 2006; 108: 1045-1049. (Pubitemid 44154643)
34. Meijerink J, Mandigers C, van de Locht L, Tonnissen E, Goodsaid F, Raemaekers J. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diagn 2001; 3: 55-61. (Pubitemid 32440243)
35. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 18-24. (Pubitemid 26019992)
36. Moricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dordelmann M et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008; 111: 4477-4489.
37. Buitenkamp T, Forestier E, Heerema NA, van den Heuvel MM, Pieters R, de Haas V et al. Acute lymphoblastic leukemia in children with Down syndrome: a report from the Ponti di Legno Study groupASH: San Diego 2011.
38. Mitchell C, Richards S, Harrison CJ, Eden T. Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001. Leukemia 2010; 24: 406-418.
39. Zeller B, Gustafsson G, Forestier E, Abrahamsson J, Clausen N, Heldrup J et al. Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol 2005; 128: 797-804. (Pubitemid 40444872)
40. Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2005; 106: 4043-4049. (Pubitemid 41775907)
41. Maloney KW, Carroll WL, Carroll AJ, Devidas M, Borowitz MJ, Martin PL et al. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. Blood 2010; 116: 1045-1050.
42. Dordelmann M, Schrappe M, Reiter A, Zimmermann M, Graf N, Schott G et al. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Munster Group. Leukemia 1998; 12: 645-651. (Pubitemid 28220815)
43. Chessells JM, Harrison G, Richards SM, Bailey CC, Hill FG, Gibson BE et al. Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch Dis Child 2001; 85: 321-325. (Pubitemid 32929599)
44. Kuiper RP, Schoenmakers EF, van Reijmersdal SV, Hehir-Kwa JY, van Kessel AG, van Leeuwen FN et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia 2007; 21: 1258-1266. (Pubitemid 46831815)